Aziz Nazha, MD
Hematology & Oncology · Cleveland, OHNPI 1508132382
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,521 of the $79,198 with a category attached, or 70.1%. 11 manufacturers reported payments, led by Incyte Corporation at 54.0% of the total. Reporting peaked in 2020 at $40,034 and has fallen 100.0% since, to $14 in 2022. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $1257.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$43K
- Novartis$15K
- Daiichi Sankyo Inc.$11K
- Boehringer Ingelheim Pharma GmbH & Co.kg$4K
- AbbVie$4K
- Gilead$790
- plus $1K from 5 others
Across 16 payments — averaging $179,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$2.8M
- PTC Therapeutics, Inc.$93K
- Sumitomo Pharma America, Inc.$7K
What the payments were for
- Consulting fees$17,30522%
- Speaking & faculty fees$55,52170%
- Travel & lodging$5,0346%
- Food & beverage$1,3272%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 36 | $42,797 |
| Novartis | 9 | $15,480 |
| Daiichi Sankyo Inc. | 2 | $10,822 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $4,201 |
| AbbVie | 7 | $4,049 |
| Gilead | 1 | $790 |
| E.r. Squibb & Sons, L.L.C. | 1 | $500 |
| Astellas Pharma US Inc | 2 | $375 |
| PTC Therapeutics, Inc. | 1 | $107 |
| Bristol Myers Squibb | 1 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,198 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.